Results 141 to 150 of about 590,194 (288)

Current status of meningococcal group B vaccine candidates: capsular or noncapsular? [PDF]

, 1994
José Diaz‐Romero, I Outschoorn
openalex   +1 more source

Advances in meningococcal vaccines

Clinical Practice, 2012
SUMMARY During the 20th century, meningococcal vaccine manufacturers took advantage of conjugate technology to provide products that could protect infants, the most vulnerable population, against invasive disease caused by serogroup C. These conjugate vaccines induce anamnestic responses and induce herd protection.
Lisa DeTora, James Wassil, Mariagrazia Pizza   +2 more
openaire   +2 more sources

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

Expert Review of Vaccines, 2018
Introduction: Menveo, quadrivalent meningococcal ACWY-CRM conjugate vaccine, was first licensed in 2010 in the United States and has a long track record of immunogenicity and safety in all age groups, including infants from 2 months of age. Areas covered:
Pavitra Keshavan, M. Pellegrini, Kumaran Vadivelu-Pechai, M. Nissen   +3 more
semanticscholar   +1 more source

Reactogenicity of hexavalent vaccines modelled in Swedish birth cohorts

Acta Paediatrica, Volume 114, Issue 2, Page 440-441, February 2025.
George Marina, Lundholm Lotta, Silfverdal Sven Arne   +2 more
wiley   +1 more source

Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine. [PDF]

Infect Immun, 2023
Gray MC, Thomas KS, Lamb ER, Werner LM, Connolly KL, Jerse AE, Criss AK.   +6 more
europepmc   +1 more source

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine

PLoS ONE, 2018
Background Meningococcal infection starts with colonisation of the upper respiratory tract. Mucosal immunity is important for protection against acquisition and subsequent meningococcal carriage.
M. V. van Ravenhorst, G. den Hartog, F. R. van der Klis, D. V. van Rooijen, E. Sanders, G. Berbers   +5 more
semanticscholar   +1 more source

Social Imitation Dynamics of Vaccination Driven by Vaccine Effectiveness and Beliefs [PDF]

arXiv
Declines in vaccination coverage for vaccine-preventable diseases, such as measles and chickenpox, have enabled their surprising comebacks and pose significant public health challenges in the wake of growing vaccine hesitancy. Vaccine opt-outs and refusals are often fueled by beliefs concerning perceptions of vaccine effectiveness and exaggerated risks.
arxiv  

Change in Recommendation for Meningococcal Vaccine for Travelers [PDF]

, 1999

openalex   +1 more source

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine

Pediatrics, 2017
BACKGROUND: Meningococcal conjugate vaccines were licensed beginning in 2005 on the basis of serologic end points and recommended for use in adolescents. A single dose at age 11 to 12 years was expected to provide protection through late adolescence.
A. Cohn, Jessica R Macneil, L. Harrison, R. Lynfield, A. Reingold, W. Schaffner, E. Zell, B. Plikaytis, Xin Wang, Nancy E. Messonnier   +9 more
semanticscholar   +1 more source

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022. [PDF]

mBio, 2023
Rodrigues CMC, MacDonald L, Ure R, Smith A, Cameron JC, Maiden MCJ.   +5 more
europepmc   +1 more source